All-cause costs increase exponentially with increased chronic kidney disease stage

To evaluate the economic impact of chronic kidney disease (CKD) on US health plans. A retrospective analysis identified patients with a renin-angiotensin-aldosterone system inhibitor (RAASi) prescription from an electronic medical record (EMR) database (Humedica); those with =90 days in =1 CKD stage...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The American journal of managed care 2017-06, Vol.23 (10 Suppl), p.S163-S172
Hauptverfasser:	Golestaneh, Ladan, Alvarez, Paula J, Reaven, Nancy L, Funk, Susan E, McGaughey, Karen J, Romero, Alain, Brenner, Melanie S, Onuigbo, Macaulay
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Case-Control Studies Cost of Illness Female Health administration Health Care Costs - statistics & numerical data Hospitalization - economics Humans Insurance, Health - economics Kidney Failure, Chronic - economics Kidney Failure, Chronic - pathology Length of Stay - economics Male Middle Aged Patient Readmission - economics Renal Insufficiency, Chronic - economics Renal Insufficiency, Chronic - pathology Retrospective Studies Severity of Illness Index United States
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	To evaluate the economic impact of chronic kidney disease (CKD) on US health plans. A retrospective analysis identified patients with a renin-angiotensin-aldosterone system inhibitor (RAASi) prescription from an electronic medical record (EMR) database (Humedica); those with =90 days in =1 CKD stage were selected based on estimated glomerular filtration rate or diagnosis code, and a cohort on RAASi medications without CKD was selected. Costs for specific services obtained from OptumInsight were applied to services in EMR data of patients aged
ISSN:	1936-2692